Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||ARV-110||Phase I||Actionable||In a Phase I trial, ARV-110 demonstrated safety and preliminary efficacy, resulted in an over 50% decline of PSA in 13.3% (2/15) of patients with metastatic castrate-resistant prostate cancer (J Clin Oncol 38: 2020 (suppl; abstr 3500); NCT03888612).||detail...|
|PubMed Id||Reference Title||Details|
|First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).||Full reference...|